These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

306 related articles for article (PubMed ID: 28076791)

  • 1. MLL-AF4 Spreading Identifies Binding Sites that Are Distinct from Super-Enhancers and that Govern Sensitivity to DOT1L Inhibition in Leukemia.
    Kerry J; Godfrey L; Repapi E; Tapia M; Blackledge NP; Ma H; Ballabio E; O'Byrne S; Ponthan F; Heidenreich O; Roy A; Roberts I; Konopleva M; Klose RJ; Geng H; Milne TA
    Cell Rep; 2017 Jan; 18(2):482-495. PubMed ID: 28076791
    [TBL] [Abstract][Full Text] [Related]  

  • 2. MLL-rearranged leukemia is dependent on aberrant H3K79 methylation by DOT1L.
    Bernt KM; Zhu N; Sinha AU; Vempati S; Faber J; Krivtsov AV; Feng Z; Punt N; Daigle A; Bullinger L; Pollock RM; Richon VM; Kung AL; Armstrong SA
    Cancer Cell; 2011 Jul; 20(1):66-78. PubMed ID: 21741597
    [TBL] [Abstract][Full Text] [Related]  

  • 3. H3K79 methylation profiles define murine and human MLL-AF4 leukemias.
    Krivtsov AV; Feng Z; Lemieux ME; Faber J; Vempati S; Sinha AU; Xia X; Jesneck J; Bracken AP; Silverman LB; Kutok JL; Kung AL; Armstrong SA
    Cancer Cell; 2008 Nov; 14(5):355-68. PubMed ID: 18977325
    [TBL] [Abstract][Full Text] [Related]  

  • 4. DOT1L inhibition reveals a distinct subset of enhancers dependent on H3K79 methylation.
    Godfrey L; Crump NT; Thorne R; Lau IJ; Repapi E; Dimou D; Smith AL; Harman JR; Telenius JM; Oudelaar AM; Downes DJ; Vyas P; Hughes JR; Milne TA
    Nat Commun; 2019 Jun; 10(1):2803. PubMed ID: 31243293
    [TBL] [Abstract][Full Text] [Related]  

  • 5. MLL-AF4 binds directly to a BCL-2 specific enhancer and modulates H3K27 acetylation.
    Godfrey L; Kerry J; Thorne R; Repapi E; Davies JO; Tapia M; Ballabio E; Hughes JR; Geng H; Konopleva M; Milne TA
    Exp Hematol; 2017 Mar; 47():64-75. PubMed ID: 27856324
    [TBL] [Abstract][Full Text] [Related]  

  • 6. DOT1L, the H3K79 methyltransferase, is required for MLL-AF9-mediated leukemogenesis.
    Nguyen AT; Taranova O; He J; Zhang Y
    Blood; 2011 Jun; 117(25):6912-22. PubMed ID: 21521783
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Complementary activities of DOT1L and Menin inhibitors in MLL-rearranged leukemia.
    Dafflon C; Craig VJ; Méreau H; Gräsel J; Schacher Engstler B; Hoffman G; Nigsch F; Gaulis S; Barys L; Ito M; Aguadé-Gorgorió J; Bornhauser B; Bourquin JP; Proske A; Stork-Fux C; Murakami M; Sellers WR; Hofmann F; Schwaller J; Tiedt R
    Leukemia; 2017 Jun; 31(6):1269-1277. PubMed ID: 27840424
    [TBL] [Abstract][Full Text] [Related]  

  • 8. DOT1L inhibits SIRT1-mediated epigenetic silencing to maintain leukemic gene expression in MLL-rearranged leukemia.
    Chen CW; Koche RP; Sinha AU; Deshpande AJ; Zhu N; Eng R; Doench JG; Xu H; Chu SH; Qi J; Wang X; Delaney C; Bernt KM; Root DE; Hahn WC; Bradner JE; Armstrong SA
    Nat Med; 2015 Apr; 21(4):335-43. PubMed ID: 25822366
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Degree of recruitment of DOT1L to MLL-AF9 defines level of H3K79 Di- and tri-methylation on target genes and transformation potential.
    Kuntimaddi A; Achille NJ; Thorpe J; Lokken AA; Singh R; Hemenway CS; Adli M; Zeleznik-Le NJ; Bushweller JH
    Cell Rep; 2015 May; 11(5):808-20. PubMed ID: 25921540
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The lncRNA LAMP5-AS1 drives leukemia cell stemness by directly modulating DOT1L methyltransferase activity in MLL leukemia.
    Wang WT; Chen TQ; Zeng ZC; Pan Q; Huang W; Han C; Fang K; Sun LY; Yang QQ; Wang D; Luo XQ; Sun YM; Chen YQ
    J Hematol Oncol; 2020 Jun; 13(1):78. PubMed ID: 32552847
    [TBL] [Abstract][Full Text] [Related]  

  • 11. H3K79me2/3 controls enhancer-promoter interactions and activation of the pan-cancer stem cell marker PROM1/CD133 in MLL-AF4 leukemia cells.
    Godfrey L; Crump NT; O'Byrne S; Lau IJ; Rice S; Harman JR; Jackson T; Elliott N; Buck G; Connor C; Thorne R; Knapp DJHF; Heidenreich O; Vyas P; Menendez P; Inglott S; Ancliff P; Geng H; Roberts I; Roy A; Milne TA
    Leukemia; 2021 Jan; 35(1):90-106. PubMed ID: 32242051
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Perturbation of Methionine/S-adenosylmethionine Metabolism as a Novel Vulnerability in MLL Rearranged Leukemia.
    Barve A; Vega A; Shah PP; Ghare S; Casson L; Wunderlich M; Siskind LJ; Beverly LJ
    Cells; 2019 Oct; 8(11):. PubMed ID: 31717699
    [TBL] [Abstract][Full Text] [Related]  

  • 13. ASH1L Links Histone H3 Lysine 36 Dimethylation to MLL Leukemia.
    Zhu L; Li Q; Wong SH; Huang M; Klein BJ; Shen J; Ikenouye L; Onishi M; Schneidawind D; Buechele C; Hansen L; Duque-Afonso J; Zhu F; Martin GM; Gozani O; Majeti R; Kutateladze TG; Cleary ML
    Cancer Discov; 2016 Jul; 6(7):770-83. PubMed ID: 27154821
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Functional diversity of inhibitors tackling the differentiation blockage of MLL-rearranged leukemia.
    Brzezinka K; Nevedomskaya E; Lesche R; Steckel M; Eheim AL; Haegebarth A; Stresemann C
    J Hematol Oncol; 2019 Jun; 12(1):66. PubMed ID: 31253180
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Function of leukemogenic mixed lineage leukemia 1 (MLL) fusion proteins through distinct partner protein complexes.
    Biswas D; Milne TA; Basrur V; Kim J; Elenitoba-Johnson KS; Allis CD; Roeder RG
    Proc Natl Acad Sci U S A; 2011 Sep; 108(38):15751-6. PubMed ID: 21896721
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Design, Synthesis, and Biological Evaluations of DOT1L Peptide Mimetics Targeting the Protein-Protein Interactions between DOT1L and MLL-AF9/MLL-ENL.
    Yuan Y; Du L; Tan R; Yu Y; Jiang J; Yao A; Luo J; Tang R; Xiao Y; Sun H
    J Med Chem; 2022 Jun; 65(11):7770-7785. PubMed ID: 35612819
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pharmacological inhibition of LSD1 for the treatment of MLL-rearranged leukemia.
    Feng Z; Yao Y; Zhou C; Chen F; Wu F; Wei L; Liu W; Dong S; Redell M; Mo Q; Song Y
    J Hematol Oncol; 2016 Mar; 9():24. PubMed ID: 26970896
    [TBL] [Abstract][Full Text] [Related]  

  • 18. MLL-AF9 and MLL-AF4 oncofusion proteins bind a distinct enhancer repertoire and target the RUNX1 program in 11q23 acute myeloid leukemia.
    Prange KHM; Mandoli A; Kuznetsova T; Wang SY; Sotoca AM; Marneth AE; van der Reijden BA; Stunnenberg HG; Martens JHA
    Oncogene; 2017 Jun; 36(23):3346-3356. PubMed ID: 28114278
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Selective killing of mixed lineage leukemia cells by a potent small-molecule DOT1L inhibitor.
    Daigle SR; Olhava EJ; Therkelsen CA; Majer CR; Sneeringer CJ; Song J; Johnston LD; Scott MP; Smith JJ; Xiao Y; Jin L; Kuntz KW; Chesworth R; Moyer MP; Bernt KM; Tseng JC; Kung AL; Armstrong SA; Copeland RA; Richon VM; Pollock RM
    Cancer Cell; 2011 Jul; 20(1):53-65. PubMed ID: 21741596
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Small-molecule inhibitor of AF9/ENL-DOT1L/AF4/AFF4 interactions suppresses malignant gene expression and tumor growth.
    Wu F; Nie S; Yao Y; Huo T; Li X; Wu X; Zhao J; Lin YL; Zhang Y; Mo Q; Song Y
    Theranostics; 2021; 11(17):8172-8184. PubMed ID: 34373735
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.